Research outputs

@article{Hunt2026,

title = {Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion},

author = {Adrian Robert Hunt and Yohei Hashimoto and Louise O'Toole and Theodorus Leonardus Ponsioen and Nandor Jaross and Samantha Fraser-Bell and Pavol Kusenda and Socorro Alforja and Daniel Barthelmes and Mark C Gillies},

doi = {10.1136/bjo-2025-328709},

issn = {1468-2079},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {British Journal of Ophthalmology},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Fraser-Bell2026,

title = {Outcomes of eyes with persistent diabetic macular oedema: The Fight Retinal Blindness! Project},

author = {Samantha Fraser-Bell and Natalie Si-Yi Lee and Yohei Hashimoto and Andreas Pollreisz and Antonella Witmer and Francesco Viola and Francisco Javier Lavid and Helen Steiner and Pierre-Henry Gabrielle and Richard Barry and Rufino Silva and Daniel Barthelmes and Mark C Gillies},

doi = {10.1136/bjo-2025-328621},

issn = {1468-2079},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {British Journal of Ophthalmology},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Franquesa-Garcia2026,

title = {Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project},

author = {Francesc Franquesa-Garcia and Barbara Romero-Nunez and Ruben Martin-Pinardel and Sandro De Zanet and Julio Jose Gonzalez-Lopez and Jose Juan Escobar-Barranco and Maria P Ruiz-Del-Tiempo and Anna Boixadera and Alex Fonollosa and Alba Gomez-Benlloch and Daniel Velazquez-Villoria and Jose Ignacio Fernandez-Vigo and Gonzaga Garay-Aramburu and Alba Parrado-Carrillo and Luis Castillon and Sandra Gomez Sanchez and Francisco Javier Lavid and Carolina Arruabarrena and Marc Figueras-Roca and Carolina Bernal-Morales and Carlos Ciller and Javier Zarranz-Ventura},

doi = {10.1136/bjo-2025-328172},

issn = {1468-2079},

year  = {2026},

date = {2026-00-00},

urldate = {2026-00-00},

journal = {British Journal of Ophthalmology},

volume = {110},

number = {8},

pages = {892–898},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Hashimoto2025,

title = {Outlier ophthalmologists in the treatment of neovascular age-related macular degeneration with intravitreal therapy},

author = {Yohei Hashimoto and Adrian Robert Hunt and Jane M Wells and Gayatri Banerjee and Ross Ferrier and Richard Barry and Andrew Field and Justin Game and Claire Yvonne Hooper and Daniel Barthelmes and Mark C Gillies},

doi = {10.1136/bjo-2024-326024},

issn = {1468-2079},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {British Journal of Ophthalmology},

volume = {109},

number = {5},

pages = {606–613},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Hashimoto2025b,

title = {Differentiating treatment episodes from gaps in eyes with diabetic macular oedema},

author = {Yohei Hashimoto and Adrian Robert Hunt and Rufino Silva and Antonella Witmer and Wajiha Jurdi Kheir and Francesco Viola and Maite Arrazola and Mohamed Moghazy Mahgoub and Andreas Pollreisz and Zanne Harvey and Daniel Barthelmes and Mark C Gillies},

doi = {10.1136/bjo-2025-327238},

issn = {1468-2079},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {British Journal of Ophthalmology},

volume = {109},

number = {11},

pages = {1279–1282},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Tan2025b,

title = {Long-term comparative outcomes of Hydrus versus iStent inject microinvasive glaucoma surgery implants combined with cataract surgery},

author = {Jeremy C K Tan and Colin Clement and Paul Healey and Ridia Lim and Andrew White and Joshua Yuen and Ashish Agar and Mitchell Lawlor},

doi = {10.1136/bjo-2025-327359},

issn = {1468-2079},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {British Journal of Ophthalmology},

volume = {110},

number = {1},

pages = {52–58},

keywords = {British Journal of Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Arnould2024,

title = {Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry},

author = {Louis Arnould and Elise Balsat and Yohei Hashimoto and Andrew White and George Kong and Hamish Dunn and Leo Fan and Pierre-Henry Gabrielle and Alain M Bron and Catherine P Creuzot-Garcher and Mitchell Lawlor},

doi = {10.1136/bjo-2023-325077},

issn = {1468-2079},

year  = {2024},

date = {2024-12-00},

journal = {British Journal of Ophthalmology},

volume = {108},

number = {12},

pages = {1672–1678},

publisher = {BMJ},

abstract = {Objective To evaluate efficacy and safety outcomes of the Xen 45 gel stent implant over 24 months of follow-up. Methods A retrospective analysis of prospectively collected data from the Fight Glaucoma Blindness observational registry. Complete success (CS) was defined as intraocular pressure (IOP) reduction ≥20% from preoperative and an IOP ≤18 mm Hg and ≥6 mm Hg with no secondary procedure at 2 years and without IOP-lowering medications. Qualified success (QS) was defined similarly, allowing the use of IOP-lowering medications. Results The Xen 45 gel stent implant was implanted in 646 eyes of 515 patients. Preoperative IOP was 21.4±7.6 (mean±SD) mm Hg on 2.7±1.3 IOP-lowering medication and mean deviation was −10.2±8.4 dB. After 24-month follow-up, IOP was 16.8±7.3 mm Hg (mean reduction of 21.7%) on 1.2±1.4 IOP-lowering medications. CS and QS rates at 24 months were 26% and 48%, respectively. CS and QS were higher in the Xen stand-alone group (33% and 52%, respectively) than in the Xen+cataract group (16% and 42%, respectively). Bleb needling was performed in 28.4% of cases, and 18% underwent a secondary procedure. Conclusions The Xen 45 gel stent implant offers acceptable long-term efficacy for the treatment of open-angle glaucoma. However, there is a significant rate of reoperation and needling, and outcomes are less effective if combined with cataract surgery.},

keywords = {British Journal of Ophthalmology, Fight Glaucoma Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Catt2023,

title = {Development of a joint set of database parameters for the EU-ROP and Fight Childhood Blindness! ROP Registries},

author = {Caroline Catt and Johanna M Pfeil and Daniel Barthelmes and Glen A Gole and Tim U Krohne and Wei-Chi Wu and Shunji Kusaka and Peiquan Zhao and Shuan Dai and James Elder and Matthias Heckmann and Jacqueline Stack and Gigi Khonyongwa-Fernandez and Andreas Stahl},

doi = {10.1136/bjo-2023-323915},

issn = {1468-2079},

year  = {2024},

date = {2024-07-00},

journal = {British Journal of Ophthalmology},

volume = {108},

number = {7},

pages = {1030–1037},

publisher = {BMJ},

abstract = {Background/Aims The incidence of retinopathy of prematurity (ROP) is increasing and treatment options are expanding, often without accompanying safety data. We aimed to define a minimal, patient-centred data set that is feasible to collect in clinical practice and can be used collaboratively to track and compare outcomes of ROP treatment with a view to improving patient outcomes. Methods A multinational group of clinicians and a patient representative with expertise in ROP and registry development collaborated to develop a data set that focused on real-world parameters and outcomes that were patient centred, minimal and feasible to collect in routine clinical practice. Results For babies receiving ROP treatment, we recommend patient demographics, systemic comorbidities, ROP status, treatment details, ophthalmic and systemic complications of treatment, ophthalmic and neurodevelopmental outcomes at initial treatment, any episodes of retreatment and follow-up examinations in the short and long-term to be collected for use in ROP studies, registries and routine clinical practice. Conclusions We recommend these parameters to be used in registries and future studies of ROP treatment, to reduce the variation seen in previous reports and allow meaningful assessments and comparisons. They form the basis of the EU-ROP and the Fight Childhood Blindness! ROP Registries.},

keywords = {British Journal of Ophthalmology, Fight Childhood Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Hunt2022,

title = {Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry},

author = {Adrian Robert Hunt and Vuong Nguyen and Jennifer J Arnold and Ian L McAllister and Hemal Mehta and Alessandro Invernizzi and Theodorus Ponsioen and Pierre-Henry Gabrielle and Louise O'Toole and Pavol Kusenda and Socorro Alforja and Daniel Barthelmes and Mark C Gillies},

doi = {10.1136/bjophthalmol-2021-320482},

issn = {1468-2079},

year  = {2023},

date = {2023-06-00},

journal = {British Journal of Ophthalmology},

volume = {107},

number = {6},

pages = {842–848},

publisher = {BMJ},

abstract = {Background/aims To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naïve hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care. Methods A database observational study recruited 79 HRVO eyes, 590 BRVO eyes and 344 CRVO eyes that initiated therapy over 10 years. The primary outcome was mean change in visual acuity (VA—letters read on a logarithm of minimal angle of resolution chart) at 12 months. Secondary outcomes included mean change in central subfield thickness (CST), injections and visits. Results At baseline, mean VA in HRVO (53.8) was similar to CRVO (51.9; p=0.40) but lower than BRVO (59.4; p=0.009). HRVO eyes improved to match BRVO eyes from soon after treatment started through 12 months. Mean change in VA was greater in HRVO (+16.4) than both BRVO (+11.4; p=0.006) and CRVO (+8.5; p<0.001). Mean change in CST in HRVO (−231 µm) was similar to CRVO (−259 µm; p=0.33) but greater than BRVO eyes (−151 µm; p=0.003). The groups had similar median burdens of eight injections and nine visits. Conclusions HRVO generally experienced the greatest mean change in VA of the three types of RVO when treated with VEGF inhibitors, ending with similar 12-month VA and CST to BRVO despite starting closer to CRVO. Inclusion of HRVO in BRVO or CRVO cohorts of clinical trials would be expected to proportionally inflate and skew the visual and anatomic outcomes.},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Ferdi2021,

title = {Predictors of progression in untreated keratoconus: a Save Sight Keratoconus Registry study},

author = {Alex Ferdi and Vuong Nguyen and Himal Kandel and Jeremy C K Tan and Francisco Arnalich-Montiel and Marco Abbondanza and Stephanie Watson},

doi = {10.1136/bjophthalmol-2020-317547},

issn = {1468-2079},

year  = {2022},

date = {2022-09-00},

journal = {British Journal of Ophthalmology},

volume = {106},

number = {9},

pages = {1206–1211},

publisher = {BMJ},

abstract = {Aims We set out to identify risk factors for progression in untreated keratoconus patients from 34 centres across Australia, New Zealand, Spain and Italy. Methods Patients were divided into ‘progressors’ and ‘stable’ patients for each clinical parameter: visual acuity (VA), steepest keratometry (maximum keratometry (Max-K)) and thinnest corneal thickness (TCT). Primary outcomes were the proportion of eyes with sustained progression in VA, Max-K or TCT within 3 years. Secondary outcomes included predictors of progression. Results There were 3994 untreated eyes from 2283 patients. The proportion of eyes with VA, Max-K and TCT progression at 1 year were 3.2%, 6.6% and 3.1% respectively. Factors associated with VA loss were higher baseline VA (HR 1.15 per logMAR line increase in VA; p<0.001) and steeper baseline Max-K (HR 1.07 per 1D increase; p<0.001). Younger baseline age was associated with Max-K steepening (HR 0.96 per year older; p=0.001). Thicker baseline TCT, steeper baseline Max-K and younger baseline age were associated with TCT thinning: (HR 1.08 per 10 µm increase in TCT; p<0.001), (HR 1.03 per 1D increase; p=0.02) and (HR 0.98 per year younger; p=0.01), respectively. Conclusions Steeper Max-K and younger age were the most clinically useful baseline predictors of progression as they were associated with worsening of two clinical parameters. Every 1D steeper Max-K was associated with a 7% and 3% greater risk of worsening VA and thinning TCT, respectively. Each 1 year younger was associated with a 4% and 2% greater risk of steepening Max-K and thinning TCT, respectively.},

keywords = {British Journal of Ophthalmology, Fight Corneal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Hunt2021,

title = {Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry},

author = {Adrian R Hunt and Vuong Nguyen and Catherine P Creuzot-Garcher and Socorro Alforja and Pierre-Henry Gabrielle and Javier Zarranz-Ventura and Martin Guillemin and Samantha Fraser-Bell and Ricardo P Casaroli Marano and Jennifer Arnold and Ian L McAllister and Louise O'Toole and Mark C Gillies and Daniel Barthelmes and Hemal Mehta},

doi = {10.1136/bjophthalmol-2020-318491},

issn = {1468-2079},

year  = {2021},

date = {2021-03-12},

journal = {British Journal of Ophthalmology},

publisher = {BMJ},

abstract = {Background/Aims To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. Methods A multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA >6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion. Results Generalised mixed effect models demonstrated that mean (95% CI) adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 (8.2 to 13.4) vs +10.9 (8.3 to 13.5) letters, respectively},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Daien2019,

title = {Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project},

author = {Vincent Daien and Vuong Nguyen and Rohan W Essex and Robin Guymer and Jennifer J Arnold and Marion Munk and Lala Ceklic and Mark C Gillies and Daniel Barthelmes},

doi = {10.1136/bjophthalmol-2019-315055},

issn = {1468-2079},

year  = {2020},

date = {2020-08-00},

journal = {British Journal of Ophthalmology},

volume = {104},

number = {8},

pages = {1064–1069},

publisher = {BMJ},

abstract = {Background To assess the prevalence and characteristics associated with macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD) treated with vascular endothelial growth factor (VEGF) inhibitors. Methods This was a retrospective, cross-sectional study of nAMD eyes that commenced anti-VEGF between January 2006 and August 2016. MA (absent/extrafoveal/subfoveal) was graded by treating practitioners based on multimodal imaging from April 2016. The prevalence of MA over time and risk factors of MA were assessed. Results The prevalence of MA in a cohort of 1689 eyes was 9.9% (22/222) in eyes within 1 year of starting treatment, 41.5% (71/171) after 5 years and 48.4% (30/62) after 9 years of treatment. Risk factors for subfoveal MA included the proportion of visits at which the lesion was graded as inactive ((adjusted OR (AOR) 3.72 for the highest vs lowest the quartile of frequency of inactive gradings (95% CI 2.33 to 6.07)), age (AOR 1.05 per year (95% CI 1.02 to 1.07)), baseline visual acuity (AOR 3.9 for ≤35 letters vs ≥70 letters (95% CI 2.4 to 6.4)) and the number of injections received (AOR 1.20 every 10 injections (95% CI 1.08 to 1.33)). Similar associations were observed with extrafoveal MA. Conclusions The risk of MA appeared to drop in eyes that had not developed it within 5 years. Low choroidal neovascularisation activity was by far the strongest predictor. We could not determine whether the increased prevalence of MA with time was due to anti-VEGF treatment or the natural history of the condition.},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Invernizzi2018,

title = {Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months},

author = {Alessandro Invernizzi and Kelvin Teo and Vuong Nguyen and Mark Daniell and David Squirrell and Daniel Barthelmes and Mark C Gillies},

doi = {10.1136/bjophthalmol-2018-312944},

issn = {1468-2079},

year  = {2019},

date = {2019-09-00},

journal = {British Journal of Ophthalmology},

volume = {103},

number = {9},

pages = {1337–1341},

publisher = {BMJ},

abstract = {Aims To compare 24 months outcomes of eyes with retinal angiomatous proliferations (RAPs) treated with antivascular endothelial growth factor (anti-VEGF) with a group of controls diagnosed with other neovascular age-related macular degeneration (nAMD) subtypes in a real-world setting. Methods Treatment-naïve nAMD eyes that commenced anti-VEGF between January 2006 and November 2015 were identified from a registry of nAMD treatment outcomes. Cases were defined as eyes diagnosed with RAP. Three controls per case were selected among nAMD eyes with non-RAP lesions and matched on baseline visual acuity (VA), year of treatment initiation, anti-VEGF agent first injected and follow-up. Baseline VA was compared with 12 and 24 months VA. Change in VA, number of injections received, proportion of visits with active nAMD and time to first inactivation were compared between RAPs and controls. Results 157 RAPs and 469 controls were included. Baseline VA (mean (SD)) increased at 12 months (61.4 (15.5) vs 68.7 (14.7) letters, p<0.001) and remained higher (66.6 (17.3) letters) at 24 months (p<0.001) in RAPs. The change from baseline VA (mean(95% CI)) was significantly higher in RAPs than in controls at 12 months (7.3 (5.4 to 9.1) vs 4.1 (2.8 to 5.4) letters},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Essex2018,

title = {Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study},

author = {Rohan W Essex and Vuong Nguyen and Vincent Daien and Sarah Steinmann and Richard Walton and Mark C Gillies and Daniel Barthelmes},

doi = {10.1136/bjophthalmol-2018-311852},

issn = {1468-2079},

year  = {2019},

date = {2019-08-00},

journal = {British Journal of Ophthalmology},

volume = {103},

number = {8},

pages = {1158–1162},

publisher = {BMJ},

abstract = {Objective To compare the outcomes of trainee-led and specialist-led management of neovascular age-related macular degeneration. Design Prospective multicentre registry-based observational study. Setting Ophthalmology training centres in Australia and Europe where both trainee-led and specialist-led models of care coexist. Participants Treatment-naïve eyes with neovascular age-related macular degeneration and at least 12 months follow-up. 726 eyes were included in the study from two centres, 534 receiving trainee-led treatment and 192 specialist-led treatment. Interventions The management and outcomes of patients receiving trainee-led care were compared with those receiving specialist-led care. Main outcomes measures The primary outcome was the mean change in visual acuity at 12 months from first injection. Outcomes were also presented at 36 months where available. Results The mean age of participants was 79 years and 65% were female. The adjusted change in acuity at 12 months in trainee-led vs specialist-led eyes was +3.2 letters vs +4.1 letters (difference −0.9 letters, 95% CI −3.4 to 1.5},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Barthelmes2016,

title = {Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration},

author = {Daniel Barthelmes and Anna Campain and Phuc Nguyen and Jennifer J Arnold and Ian L McAllister and Judy M Simpson and Alex P Hunyor and Robyn Guymer and Rohan W Essex and Nigel Morlet and Mark C Gillies},

doi = {10.1136/bjophthalmol-2015-308090},

issn = {1468-2079},

year  = {2016},

date = {2016-12-00},

journal = {British Journal of Ophthalmology},

volume = {100},

number = {12},

pages = {1640–1645},

publisher = {BMJ},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Barthelmes2014,

title = {Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data},

author = {Daniel Barthelmes and Richard Walton and Anna E Campain and Judy M Simpson and Jennifer J Arnold and Ian L McAllister and Robyn H Guymer and Alex P Hunyor and Rohan W Essex and Nigel Morlet and Mark C Gillies},

doi = {10.1136/bjophthalmol-2014-305514},

issn = {1468-2079},

year  = {2015},

date = {2015-03-00},

journal = {British Journal of Ophthalmology},

volume = {99},

number = {3},

pages = {359–364},

publisher = {BMJ},

keywords = {British Journal of Ophthalmology, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}